{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T07:49:25Z","timestamp":1791532165234,"version":"4.3.4"},"reference-count":86,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014620","name":"Micropalaeontological Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014620","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jtct.2026.06.001","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:04:05Z","timestamp":1780963445000},"page":"1223-1238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Monospecific and Bispecific Chimeric Antigen Receptor (CAR) T-cell Therapy in Multiple Myeloma: A Systematic Review, Meta-analysis and Meta-regression"],"prefix":"10.1016","volume":"32","author":[{"given":"Ainsley Ryan Yan Bin","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9274-0406","authenticated-orcid":false,"given":"Hon Jen","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5447-5092","authenticated-orcid":false,"given":"Chi Ching","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"De Mel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7392-0655","authenticated-orcid":false,"given":"Melissa","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Joo","family":"Chng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Yang","family":"Soon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinnie Yentia","family":"Soekojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jtct.2026.06.001_bib0001","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.jtct.2026.06.001_bib0002","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.jtct.2026.06.001_bib0003","doi-asserted-by":"crossref","first-page":"e412","DOI":"10.3324\/haematol.2017.183475","article-title":"Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study","volume":"103","author":"Thorsteinsdottir","year":"2018","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.001_bib0004","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12885-023-10787-5","article-title":"Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany","volume":"23","author":"Eisfeld","year":"2023","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.jtct.2026.06.001_bib0005","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.3390\/curroncol30020179","article-title":"Relapsed\/refractory multiple myeloma: a review of available therapies and clinical scenarios encountered in myeloma relapse","volume":"30","author":"Bhatt","year":"2023","journal-title":"Curr Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2026.06.001_bib0006","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.001_bib0007","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41408-024-01191-8","article-title":"CAR-T cell therapy in multiple myeloma: current status and future challenges","volume":"14","author":"Swan","year":"2024","journal-title":"Blood Cancer J"},{"issue":"11","key":"10.1016\/j.jtct.2026.06.001_bib0008","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jtct.2026.06.001_bib0009","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2024-0080","article-title":"Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting","volume":"13","author":"Alsdorf WD","year":"2024","journal-title":"J Comp Eff Res"},{"issue":"14","key":"10.1016\/j.jtct.2026.06.001_bib0010","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1200\/JCO.22.01824","article-title":"Anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase \u2161 trial","volume":"41","author":"Xia JL","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jtct.2026.06.001_bib0011","doi-asserted-by":"crossref","first-page":"e751","DOI":"10.1016\/S2352-3026(24)00176-5","article-title":"Anti-BCMA\/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial","volume":"11","author":"Zhou","year":"2024","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.001_bib0012","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1038\/s41467-024-47801-8","article-title":"Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed\/refractory multiple myeloma: a phase I\/II trial","volume":"15","author":"Shi","year":"2024","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.jtct.2026.06.001_bib0013","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11899-023-00687-7","article-title":"CAR-T cell therapy: the efficacy and toxicity balance","volume":"18","author":"Chohan","year":"2023","journal-title":"Curr Hematol Malig Rep"},{"issue":"3","key":"10.1016\/j.jtct.2026.06.001_bib0014","first-page":"300","article-title":"Toxicity of CAR T-cell therapy for multiple myeloma","volume":"148","author":"Afrough","year":"2025","journal-title":"Acta Haematol"},{"key":"10.1016\/j.jtct.2026.06.001_bib0015","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.jtct.2026.06.001_bib0016","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"issue":"25","key":"10.1016\/j.jtct.2026.06.001_bib0017","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1002\/sim.2889","article-title":"Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity","volume":"26","author":"Peters","year":"2007","journal-title":"Stat Med"},{"issue":"7109","key":"10.1016\/j.jtct.2026.06.001_bib0018","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.jtct.2026.06.001_bib0019","doi-asserted-by":"crossref","first-page":"378","DOI":"10.11124\/JBIES-23-00268","article-title":"The revised JBI critical appraisal tool for the assessment of risk of bias for quasi-experimental studies","volume":"22","author":"Barker","year":"2024","journal-title":"JBI Evid Synth"},{"issue":"7650","key":"10.1016\/j.jtct.2026.06.001_bib0020","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"23","key":"10.1016\/j.jtct.2026.06.001_bib0021","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1182\/blood.2024024582","article-title":"Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses","volume":"144","author":"Ailawadhi","year":"2024","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.jtct.2026.06.001_bib0022","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2026.06.001_bib0023","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.346","article-title":"A phase I study of anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma and plasma cell leukemia","volume":"11","author":"Li","year":"2021","journal-title":"Clin Transl Med"},{"issue":"21","key":"10.1016\/j.jtct.2026.06.001_bib0024","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/blood.2020008936","article-title":"A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma","volume":"137","author":"Wang","year":"2021","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2026.06.001_bib0025","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jamaoncol.2024.4879","article-title":"Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: the FUMANBA-1 nonrandomized clinical trial","volume":"10","author":"Li","year":"2024","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2026.06.001_bib0026","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1158\/2643-3230.BCD-22-0074","article-title":"Anti-BCMA\/CD19 CAR T cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy","volume":"4","author":"Garfall","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"9","key":"10.1016\/j.jtct.2026.06.001_bib0027","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","article-title":"Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial","volume":"29","author":"Lin","year":"2023","journal-title":"Nat Med"},{"issue":"18","key":"10.1016\/j.jtct.2026.06.001_bib0028","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.001_bib0029","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13045-024-01530-z","article-title":"Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial","volume":"17","author":"Xu","year":"2024","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.001_bib0030","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.001_bib0031","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-022-01301-8","article-title":"Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)","volume":"15","author":"Zhao","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"19","key":"10.1016\/j.jtct.2026.06.001_bib0032","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma","volume":"116","author":"Xu","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"10.1016\/j.jtct.2026.06.001_bib0033","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/ajh.26583","article-title":"CAR-T cell therapy targeting B cell maturation antigen is effective for relapsed\/refractory multiple myeloma, including cases with poor performance status","volume":"97","author":"Du","year":"2022","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.jtct.2026.06.001_bib0034","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/blood.2024027681","article-title":"A phase 1 trial of fully human BCMA CAR-T therapy for relapsed\/refractory multiple myeloma with 5-year follow-up","volume":"146","author":"Tuazon","year":"2025","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2026.06.001_bib0035","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jtct.2026.06.001_bib0036","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S1470-2045(23)00246-2","article-title":"Gamma-secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial","volume":"24","author":"Cowan","year":"2023","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2026.06.001_bib0037","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.22.00690","article-title":"Phase II, open-label study of ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor-T-cell therapy, in Chinese patients with relapsed\/refractory multiple myeloma (CARTIFAN-1)","volume":"41","author":"Mi","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2026.06.001_bib0038","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005145","article-title":"Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma","volume":"10","author":"Qu","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.jtct.2026.06.001_bib0039","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","article-title":"Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results","volume":"29","author":"Mailankody","year":"2023","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.jtct.2026.06.001_bib0040","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2026.06.001_bib0041","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/bloodadvances.2022007210","article-title":"Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma","volume":"7","author":"Frigault","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.jtct.2026.06.001_bib0042","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S1470-2045(23)00222-X","article-title":"Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study","volume":"24","author":"Oliver-Caldes","year":"2023","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2026.06.001_bib0043","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/s41375-025-02518-5","article-title":"Phase 1 clinical trial of B-cell maturation antigen (BCMA) NEX-T(R) Chimeric antigen receptor (CAR) T cell therapy CC-98633\/BMS-986354 in participants with triple-class exposed multiple myeloma","volume":"39","author":"Ravi","year":"2025","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.jtct.2026.06.001_bib0044","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1182\/bloodadvances.2025016322","article-title":"Efficacy and safety of BCMA nanobody CAR T-cell therapy in relapsed or refractory plasma cell myeloma","volume":"9","author":"Zhang","year":"2025","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.001_bib0045","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1158\/2326-6066.CIR-24-0051","article-title":"CD27-armored BCMA CAR T-cell therapy (CBG-002) for relapsed and refractory multiple myeloma: a phase I clinical trial","volume":"13","author":"Xu","year":"2025","journal-title":"Cancer Immunol Res"},{"issue":"15","key":"10.1016\/j.jtct.2026.06.001_bib0046","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1182\/bloodadvances.2024012967","article-title":"Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed\/refractory multiple myeloma","volume":"8","author":"Kfir-Erenfeld","year":"2024","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.jtct.2026.06.001_bib0047","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.3324\/haematol.2022.281628","article-title":"Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed\/refractory multiple myeloma: results from a phase I clinical trial","volume":"108","author":"Asherie","year":"2023","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.jtct.2026.06.001_bib0048","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jtct.2026.06.001_bib0049","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10297","key":"10.1016\/j.jtct.2026.06.001_bib0050","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.jtct.2026.06.001_bib0051","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO-25-00760","article-title":"Long-term (>\/=5-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma","volume":"43","author":"Jagannath","year":"2025","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jtct.2026.06.001_bib0052","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.jtct.2026.06.001_bib0053","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1200\/JCO.22.01824","article-title":"Anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase \u2161 trial","volume":"41","author":"Xia","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2026.06.001_bib0054","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.1016\/S2352-3026(25)00048-1","article-title":"Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial","volume":"12","author":"Xia","year":"2025","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.jtct.2026.06.001_bib0055","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO-24-01785","article-title":"Phase I trial of MCARH109, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor T-cell therapy for multiple myeloma: an updated analysis","volume":"43","author":"Jurgens","year":"2025","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.jtct.2026.06.001_bib0056","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jtct.2026.06.001_bib0057","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S2352-3026(22)00372-6","article-title":"GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial","volume":"10","author":"Zhang","year":"2023","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.jtct.2026.06.001_bib0058","doi-asserted-by":"crossref","first-page":"e798","DOI":"10.1016\/S2352-3026(25)00176-0","article-title":"GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial","volume":"12","author":"Jin","year":"2025","journal-title":"Lancet Haematol"},{"issue":"20","key":"10.1016\/j.jtct.2026.06.001_bib0059","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.21.01676","article-title":"Long-term follow-up of combination of B-cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma","volume":"40","author":"Wang","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2026.06.001_bib0060","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ajh.26486","article-title":"Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma","volume":"97","author":"Shi","year":"2022","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.jtct.2026.06.001_bib0061","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2026.06.001_bib0062","article-title":"Prolonged hematological toxicity in patients receiving BCMA\/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.jtct.2026.06.001_bib0063","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1001\/jamaoncol.2024.2172","article-title":"B-cell maturation antigen\/CD19 dual-targeting immunotherapy in newly diagnosed multiple myeloma","volume":"10","author":"Qiang","year":"2024","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.001_bib0064","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","article-title":"A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma","volume":"14","author":"Mei","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.001_bib0065","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41375-023-02065-x","article-title":"Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma","volume":"38","author":"Li","year":"2024","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.001_bib0066","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13045-025-01713-2","article-title":"BCMA\/GPRC5D bispecific CAR T-cell therapy for relapsed\/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial","volume":"18","author":"Yao","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"8","key":"10.1016\/j.jtct.2026.06.001_bib0067","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120505","article-title":"Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma","volume":"3","author":"Garfall","year":"2018","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.jtct.2026.06.001_bib0068","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.001_bib0069","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-65267-0","article-title":"T(SCM)-predominant allogeneic anti-BCMA CAR-T therapy for relapsed\/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial","volume":"16","author":"Tseng","year":"2025","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.jtct.2026.06.001_bib0070","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/ajh.27469","article-title":"Clinical outcomes and microenvironment profiling in relapsed\/refractory multiple myeloma patients with extramedullary disease receiving anti-BCMA CAR T-cell-based therapy","volume":"99","author":"Qi","year":"2024","journal-title":"Am J Hematol"},{"issue":"23","key":"10.1016\/j.jtct.2026.06.001_bib0071","doi-asserted-by":"crossref","first-page":"6384","DOI":"10.1158\/1078-0432.CCR-21-2031","article-title":"Risk factors associated with durable progression-free survival in patients with relapsed or refractory multiple myeloma treated with anti-BCMA CAR T-cell therapy","volume":"27","author":"Zhang","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.001_bib0072","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13046-021-02214-z","article-title":"High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma","volume":"41","author":"Tang","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"Suppl 1","key":"10.1016\/j.jtct.2026.06.001_bib0073","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/jha2.350","article-title":"CAR-T-OPENIA: chimeric antigen receptor T-cell therapy-associated cytopenias","volume":"3","author":"Taneja","year":"2022","journal-title":"EJHaem"},{"issue":"20","key":"10.1016\/j.jtct.2026.06.001_bib0074","doi-asserted-by":"crossref","first-page":"34001","DOI":"10.18632\/oncotarget.16987","article-title":"Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed\/refractory multiple myeloma","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.001_bib0075","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1186\/s12885-022-09571-8","article-title":"Multinomial network meta-analysis using response rates: relapsed\/refractory multiple myeloma treatment rankings differ depending on the choice of outcome","volume":"22","author":"van Beurden-Tan","year":"2022","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.jtct.2026.06.001_bib0076","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary disease in multiple myeloma: a systematic literature review","volume":"12","author":"Blad\u00e9","year":"2022","journal-title":"Blood Cancer J"},{"issue":"15","key":"10.1016\/j.jtct.2026.06.001_bib0077","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1182\/bloodadvances.2025016619","article-title":"Extramedullary myeloma is genomically complex and characterized by near-universal MAPK pathway alterations","volume":"9","author":"Zanwar","year":"2025","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jtct.2026.06.001_bib0078","doi-asserted-by":"crossref","DOI":"10.3390\/curroncol32030182","article-title":"Extramedullary multiple myeloma: challenges and opportunities","volume":"32","author":"Ho","year":"2025","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.001_bib0079","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/14712598.2024.2443093","article-title":"Advances in CD19-targeting CAR-T cell therapies for multiple myeloma","volume":"25","author":"Steinhardt","year":"2025","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.001_bib0080","doi-asserted-by":"crossref","DOI":"10.4084\/MJHID.2025.045","article-title":"Bispecific antibodies and CAR T in multiple myeloma: appropriate selection of patients and sequencing","volume":"17","author":"Puppi","year":"2025","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.001_bib0081","first-page":"1","article-title":"Advancing multiple myeloma immunotherapy: a review of chimeric antigen receptor T-cell and bispecific T-cell engagers cell therapies in revolutionizing treatment","volume":"50","author":"Navab","year":"2025","journal-title":"Iran J Med Sci"},{"key":"10.1016\/j.jtct.2026.06.001_bib0082","article-title":"Cilta-cel salvages ide-cel failure in relapsed multiple myeloma by driving distinct immune responses","author":"Pan","year":"2025","journal-title":"medRxiv"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2026.06.001_bib0083","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.1182\/blood-2025-5764","article-title":"The efficacy of cilta-cel after a prior BCMA-directed CAR T-cell therapy in relapsed\/refractory multiple myeloma","volume":"146","author":"Attar","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.001_bib0084","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1080\/07853890.2022.2136748","article-title":"Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors","volume":"54","author":"Xia","year":"2022","journal-title":"Ann Med"},{"issue":"Suppl 3","key":"10.1016\/j.jtct.2026.06.001_bib85","first-page":"21","article-title":"CAR T-cell therapy: adverse events and management","volume":"10","author":"Adkins","year":"2019","journal-title":"J Adv Pract Oncol"},{"issue":"7","key":"10.1016\/j.jtct.2026.06.001_bib86","doi-asserted-by":"crossref","first-page":"104090","DOI":"10.1016\/j.autrev.2026.104090","article-title":"Chimeric antigen receptor-based cellular therapy in autoimmune diseases: a systematic review and meta-analysis of clinical, serological and safety outcomes","volume":"25","author":"Wong","year":"2026","journal-title":"Autoimmun Rev"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672600446X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672600446X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:58:36Z","timestamp":1791529116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266663672600446X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":86,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S266663672600446X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.06.001","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monospecific and Bispecific Chimeric Antigen Receptor (CAR) T-cell Therapy in Multiple Myeloma: A Systematic Review, Meta-analysis and Meta-regression","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}